Biomarkers of Liver Disease

Please sign in to your myUEG account to begin this course now

Chronic liver diseases are a major public health concern and confer a high economic burden. Non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma (HCC) and biliary diseases rank at the top when it comes to the need for novel biomarkers of diagnosis, progression and prognosis.

The purpose of this course is to highlight what makes a good noninvasive biomarker, explain the application of biomarkers in clinical practice and introduce microRNAs (miRNAs/miRs) and extracellular vesicles (EVs) as novel noninvasive biomarkers in the setting of liver diseases.

The course covers biomarkers of steatosis, steatohepatitis, liver fibrosis, hepatocellular carcinoma and biliary diseases. 

The estimated time needed to complete the course, including the final assessment, is  1h 15mins. 

This course was developed by: UEG.

To become familiar with:

  • The aetiology and epidemiology of NAFLD, HCC and biliary diseases
  • The need for novel biomarkers of liver disease
  • Characteristics of a good clinical biomarker
  • The spectrum of currently available noninvasive biomarkers, including their accuracy and limitations
  • The definition and function of miRNAs and EVs 
  • The role of miRNAs and EVs in NAFLD, HCC and biliary diseases
  • miRNAs and EVs as novel biomarkers of liver disease

Authors

Rui E. Castro, The Research Institute for Medicines (iMed.Lisboa) and Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon, Portugal.

Frank Tacke, Department of Medicine III, University Hospital Aachen, Aachen, Germany.

Jesús M. Bañales, Liver Diseases Group, Biodonostia Research Institute and Donostia University Hospital, Donostia, San Sebastián, Spain.

Editor
Rui Castro, The Research Institute for Medicines (iMed.Lisboa) and Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon, Portugal.

This course is suitable for hepatologists in training and scientists working in translational biomedicine, and is also appropriate for other physicians, nurses, biotechnicians, pharmacists, scientists in other disciplines and medical students who have an interest in hepatology and biomarker development.

  • The estimated time needed to complete the course, including the final assessment, is  1h 15mins. 
  • The authors and course editor have declared that they have no conflicts of interest in relation to the material in this course. 
  • The production of this course was funded entirely by UEG. No external sponsorship was received.
  • The material used in this course was prepared in September 2017.
  • Learners are invited to test their knowledge at the beginning and the end of the course via a series of 10 MCQs.
  • The course has a pass mark of 70%. Those scoring less than the required pass mark are encouraged to revisit the course and retake the assessment.

Release Date: October 2017

            This course, made available on www.ueg.eu and organised by United European Gastroenterology, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to award 1 European CME credit (ECMEC).
            Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.